Skip to main content

Advertisement

Log in

Predicting the clinical outcomes and benefit from letrozole after 5 years of treatment with aromatase inhibitors for early breast cancer: analysis from CCTG MA.17R

  • Clinical trial
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

Purpose

Women with hormone receptor positive breast cancer may receive 5 years of treatment with aromatase inhibitors but the magnitude of benefit was relatively small. Our goal was to develop a tool for identification of women with limited treatment benefit.

Methods

Regression analyses were applied to women treated by placebo in CCTG MA.17R trial (NCT00754845) to identify important prognostic factors associated with distant recurrence and develop a nomogram for predicting 5-year likelihood of distant recurrence, which was internally validated using bootstrap resampling method. Differential treatment effects between risk categories derived from the nomogram were evaluated among all women enrolled through interaction test between treatment and risk category.

Results

A total of 1735 women were included and the final model from 866 women treated by placebo identified the following three factors associate with distant recurrence: tumor size, nodal status, and presence of cardiovascular disease. The nomogram derived from the final model exhibited good discrimination power with a bootstrap-corrected concordance index of 0.71 and, importantly, identified 64% of low risk patients in whom extended treatment has limited benefit. Interaction between treatment and risk category derived from the nomogram was significant (p = 0.04).

Conclusion

A nomogram with good performance may be used to accurately predict distant recurrence risk and also benefits with extended treatment after 5 years of aromatase inhibitors. Future independent validation of the proposed nomogram is warranted.

Trial registration number

NCT00754845

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

Data availability

Data can be requested by writing to the corresponding author.

References

  1. Goss PE, Ingle JN, Martino S et al (2003) A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349:1793–1802

    Article  CAS  Google Scholar 

  2. Cuzick J, Sestak I, Baum M et al (2010) Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol 11:1135–1141

    Article  CAS  Google Scholar 

  3. Regan MM, Neven P, Giobbie-Hurder A et al (2011) Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1–98 randomised clinical trial at 8.1 years median follow-up. Lancet Oncol 12:1101–1108

    Article  CAS  Google Scholar 

  4. Ingle JN, Schaid DJ, Goss PE et al (2010) Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors. J Clin Oncol 28:4674–4682

    Article  CAS  Google Scholar 

  5. O’Leary CG, Ellis H, Higgins M (2016) Extended adjuvant endocrine therapy in hormone-receptor-positive early breast cancer. Curr Opin Oncol 28:455–460

    Article  CAS  Google Scholar 

  6. Goss PE, Ingle JN, Pritchard KI et al (2016) Extending aromatase-inhibitor adjuvant therapy to 10 years. N Engl J Med 375:209–219

    Article  CAS  Google Scholar 

  7. Sestak I, Dowsett M, Zabaglo L et al (2013) Factors predicting late recurrence for estrogen receptor-positive breast cancer. J Natl Cancer Inst 105:1504–1511

    Article  CAS  Google Scholar 

  8. Sestak I, Buus R, Cuzick J et al (2018) Comparison of the performance of 6 prognostic signatures for estrogen receptor-positive breast cancer. a secondary analysis of a randomised trial. JAMA Oncol 4:545–553

    Article  Google Scholar 

  9. Dowsett M, Sestak I, Regan MM et al (2018) Integration of clinical variables for the prediction of late distant recurrence in patients with estrogen receptor-positive breast cancer treated with 5 years of endocrine therapy: CTS5. J Clin Oncol 36:1941–1948

    Article  CAS  Google Scholar 

  10. Moreau-Bachelard C, Campion L, Robert M et al (2020) Development of a prognostic tool to guide the decision to extend adjuvant aromatase inhibitors for up to ten years in postmenopausal early breast cancer patients. Cancers 12:3725. https://doi.org/10.3390/cancers12123725

    Article  CAS  PubMed Central  Google Scholar 

  11. Satagopan JM, Ben-Porat L, Berwick M et al (2004) A note on competing risks in survival data analysis. Br J Cancer 91:1229–1235

    Article  CAS  Google Scholar 

  12. Austin PC, Lee DS, Fine JP (2016) Introduction to the analysis of survival data in the presence of competing risks. Circulation 133:601–609

    Article  Google Scholar 

  13. Ethier JL, Anderson GM, Austin PC et al (2021) Influence of the competing risk of death on estimates of disease recurrence in trials of adjuvant endocrine therapy for early-stage breast cancer: a secondary analysis of MA.27, MA.17 and MA.17R. Eur J Cancer 149:117–127

    Article  CAS  Google Scholar 

  14. Gray RJ (1988) A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16:1141–1154

    Article  Google Scholar 

  15. Fine JP, Gray RJ (1999) A proportional hazards model for the subdistribution of a competing risk. J Amer Stat Assoc 94:496–509

    Article  Google Scholar 

  16. Wolbers M, Koller M, Witteman J et al (2009) Prognostic models with competing risks: methods and application to coronary risk prediction. Epidemiology 20:555–561

    Article  Google Scholar 

  17. Gray RJ (2019) cmprsk: subdistribution analysis of competing risks. R package version 2.2-9. http://CRAN.R-project.org/package=cmprsk. Accessed 19 Nov 2021

  18. Harrell Jr FE (2019) rms: regression modeling strategies. R package version 5.1-3.1. https://CRAN.R-project.org/package=rms. Accessed 19 Nov 2021

  19. Carter CL, Allen C, Henson DE (1989) Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 63:181–187

    Article  CAS  Google Scholar 

  20. Mehta LS, Watson KE, Barac A (2018) Cardiovascular disease and breast cancer: where these entities intersect-A scientific statement from the American Heart Association. Circulation 137:e30–e66

    Article  Google Scholar 

  21. McPherson K, Steel CM, Dixon JM (2000) Breast cancer-epidemiology, risk factors, and genetics. BMJ 321:624–628

    Article  CAS  Google Scholar 

  22. West HJ, Jin JO (2015) Performance status in patients with cancer. JAMA Oncol 1:998

    Article  Google Scholar 

  23. Foldi J, O’Meara T, Marczyk M et al (2019) Defining risk of late recurrence in early-stage estrogen receptor-positive breast cancer: clinical versus molecular tools. J Clin Oncol 37:1365–1369

    Article  CAS  Google Scholar 

  24. Sgroi DC, Carney E, Zarrella E et al (2013) Prediction of late disease recurrence and extended adjuvant letrozole benefit by the HOXB13/IL17BR biomarker. J Natl Cancer Inst 105:1036–1042

    Article  CAS  Google Scholar 

  25. Filipits M, Dubsky P, Rudas M et al (2019) Prediction of distant recurrence using endopredict among women with ER(+), HER2(-) node-positive and node-negative breast cancer treated with endocrine therapy only. Clin Cancer Res 25:3865–3872

    Article  CAS  Google Scholar 

  26. Mamounas EP, Bandos H, Rastogi P et al (2021) Breast cancer index (BCI) and prediction of benefit from extended aromatase inhibitor (AI) therapy (tx) in HR+ breast cancer: NRG oncology/NSABP B-42. J Clin Onco 39:501

    Article  Google Scholar 

  27. Rastogi P, Bandos H, Lucas PC et al (2021) Utility of the 70-gene MammaPrint assay for prediction of benefit from extended letrozole therapy (ELT) in the NRG oncology/NSABP B-42 trial. J Clin Onco 39:502

    Article  Google Scholar 

Download references

Acknowledgements

None.

Funding

None.

Author information

Authors and Affiliations

Authors

Corresponding authors

Correspondence to Dongsheng Tu or Guoyou Qin.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (PDF 53 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Li, Y., Zheng, X., Tu, D. et al. Predicting the clinical outcomes and benefit from letrozole after 5 years of treatment with aromatase inhibitors for early breast cancer: analysis from CCTG MA.17R. Breast Cancer Res Treat 191, 523–533 (2022). https://doi.org/10.1007/s10549-021-06448-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-021-06448-5

Keywords

Navigation